A Study of Cancer Diagnosis as a Risk Factor for Personal Bankruptcy

癌症诊断作为个人破产风险因素的研究

基本信息

  • 批准号:
    7938057
  • 负责人:
  • 金额:
    $ 26.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-24 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This application, "A Study of Cancer Diagnosis as a Risk Factor for Personal Bankruptcy," addresses broad Challenge Area (09) Health Disparities, and Challenge Topic 09-MD-102: Trans-disciplinary Research to Integrate the Biological and Non-biological Determinants of Health to Address Health Disparities. Bankruptcy may represent a unique and heretofore unstudied determinant of health disparity. In 2008, there were more than 1 million personal bankruptcy filings, equivalent to 1 in 120 American households. Moreover, corresponding with the recent economic downturn, bankruptcy filings are increasing at an alarming rate, more than doubling since 2006. Persons entering bankruptcy following a severe illness may experience difficulties obtaining health insurance or accessing health care providers, and may not be able to complete acute treatment for the disease or obtain care for related long-run adverse effects. In a recent survey, 28% of individuals filing for bankruptcy indicated that illness or injury was a primary cause. However, because surveys of illness and bankruptcy have largely relied on self report, the true relationship remains controversial. Bankruptcy may be a particular concern for persons who are diagnosed with cancer. Media reports have highlighted cases where cancer has caused financial hardship, including bankruptcy. Among the 1.4 million persons diagnosed with cancer each year, the number filing for bankruptcy is unknown. The overall goal of this project is to determine the impact of a diagnosis of cancer on individuals' risk of incurring personal bankruptcy. To accomplish this goal, study investigators have obtained special dispensation from the Chief Judge of the U.S. Bankruptcy Court-Western District of Washington to link person-level bankruptcy records with Western Washington Surveillance Epidemiology and End Results (SEER) cancer registry records and Washington State driver's license records. This innovative study represents the first use of these databases to study cancer-related bankruptcy. The study design does not rely on self-reported data, thereby overcoming inherent weaknesses in previous research. Using a retrospective cohort design, we will estimate the relative risk of bankruptcy for adults diagnosed with cancer between 1995 and 2008 compared to adults without cancer. We will match cancer cases identified from Washington SEER records to age- and sex-matched individuals without cancer from driver's license records. Using the linked database, we will evaluate the impact of age, sex, race and ethnicity, and the patient's cancer (including cancer type, stage at diagnosis, year at diagnosis, and initial treatment) on bankruptcy risk. In separate analyses, we will link neighborhood-level Census Bureau records to evaluate the influence of socioeconomic variables (e.g., average income, percentage of home ownership). We will also examine the impact of regional factors such as the Washington State bankruptcy exemption level, lawyers per capita, and state income growth. Finally, we will examine the impact of the Bankruptcy Abuse Prevention and Consumer Protection Act of 2005 on bankruptcy filings among cancer patients, both in general and compared to persons without cancer. Our study will provide rigorous scientific evidence characterizing the relationship between cancer and personal bankruptcy. We expect these results to inform health care policy discussions. Bankruptcy may represent a unique and heretofore unstudied potential source of health disparity. In this study, we have formed a novel partnership with the Federal Bankruptcy Court and the National Cancer Institute's SEER cancer registry to link bankruptcy records for cancer patients and a matched control population without cancer. If we find that cancer patients experience excess rates of bankruptcy compared to persons without cancer, our results will have important implications for those researching the causes of cancer disparity, and for policymakers seeking to mitigate the economic as well as clinical burden of persons with cancer.
描述(由申请人提供):本申请,“癌症诊断作为个人破产风险因素的研究”,解决了广泛的挑战领域(09)健康差异和挑战主题09-MD-102:整合健康的生物和非生物决定因素以解决健康差异的跨学科研究。破产可能是一个独特的,迄今尚未研究的健康差距的决定因素。2008年,有超过100万个人申请破产,相当于每120个美国家庭中就有1个。此外,与最近的经济衰退相对应,破产申请正以惊人的速度增加,自2006年以来翻了一番多。患重病后进入破产状态的人可能难以获得医疗保险或获得医疗保健服务,可能无法完成疾病的急性治疗或获得相关长期不良影响的护理。在最近的一项调查中,28%的申请破产的个人表示,疾病或受伤是主要原因。然而,由于疾病和破产的调查在很大程度上依赖于自我报告,真正的关系仍然存在争议。破产可能是被诊断患有癌症的人特别关注的问题。媒体报道强调了癌症导致经济困难的案例,包括破产。在每年被诊断出患有癌症的140万人中,申请破产的人数不详。该项目的总体目标是确定癌症诊断对个人破产风险的影响。为了实现这一目标,研究者已获得美国破产法院-华盛顿西区首席法官的特许,将个人层面的破产记录与西部华盛顿监测流行病学和最终结果(SEER)癌症登记记录和华盛顿州驾驶执照记录联系起来。这项创新的研究代表了这些数据库的首次使用,以研究癌症相关的破产。研究设计不依赖于自我报告的数据,从而克服了以往研究的固有弱点。使用回顾性队列设计,我们将估计1995年至2008年期间诊断患有癌症的成年人与未患癌症的成年人相比破产的相对风险。我们将从华盛顿SEER记录中识别出的癌症病例与驾驶执照记录中年龄和性别匹配的无癌症个体进行匹配。使用链接的数据库,我们将评估年龄,性别,种族和民族,以及患者的癌症(包括癌症类型,诊断阶段,诊断年份和初始治疗)对破产风险的影响。在单独的分析中,我们将链接社区一级的人口普查局记录,以评估社会经济变量的影响(例如,平均收入、住房拥有率)。我们还将研究地区因素的影响,如华盛顿州破产豁免水平,律师人均,国家收入增长。最后,我们将研究2005年《破产滥用预防和消费者保护法》对癌症患者破产申请的影响,无论是在一般情况下还是与非癌症患者相比。我们的研究将提供严格的科学证据来描述癌症和个人破产之间的关系。我们希望这些结果能够为医疗保健政策的讨论提供信息。破产可能是一个独特的,迄今尚未研究的健康差距的潜在来源。在这项研究中,我们与联邦破产法院和国家癌症研究所的SEER癌症登记处建立了一种新的合作关系,将癌症患者的破产记录与无癌症的对照人群联系起来。如果我们发现癌症患者的破产率高于非癌症患者,我们的研究结果将对那些研究癌症差异原因的人以及寻求减轻癌症患者经济和临床负担的政策制定者产生重要影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SCOTT D. RAMSEY其他文献

SCOTT D. RAMSEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SCOTT D. RAMSEY', 18)}}的其他基金

The Cure Sickle Cell Initiative Economic Analysis: An Evaluation of the Costs of Sickle Cell Disease and Potential Health Plan Budget Impacts of Gene Therapy as a New Treatment Option
治愈镰状细胞倡议经济分析:镰状细胞病成本评估以及基因疗法作为新治疗方案对健康计划预算的潜在影响
  • 批准号:
    10627163
  • 财政年份:
    2019
  • 资助金额:
    $ 26.4万
  • 项目类别:
Cost Effectiveness Analysis of Stem Cell Transplant in Older MDS Patients
老年MDS患者干细胞移植的成本效益分析
  • 批准号:
    9050701
  • 财政年份:
    2015
  • 资助金额:
    $ 26.4万
  • 项目类别:
Cost Effectiveness Analysis of Stem Cell Transplant in Older MDS Patients
老年MDS患者干细胞移植的成本效益分析
  • 批准号:
    9252538
  • 财政年份:
    2015
  • 资助金额:
    $ 26.4万
  • 项目类别:
Cost Effectiveness Analysis of Stem Cell Transplant in Older MDS Patients
老年MDS患者干细胞移植的成本效益分析
  • 批准号:
    8852435
  • 财政年份:
    2015
  • 资助金额:
    $ 26.4万
  • 项目类别:
BMT CTN 1101 Ancillary Cost-Effectiveness Analysis
BMT CTN 1101 辅助成本效益分析
  • 批准号:
    8526548
  • 财政年份:
    2012
  • 资助金额:
    $ 26.4万
  • 项目类别:
BMT CTN 1101 Ancillary Cost-Effectiveness Analysis
BMT CTN 1101 辅助成本效益分析
  • 批准号:
    8415322
  • 财政年份:
    2012
  • 资助金额:
    $ 26.4万
  • 项目类别:
BMT CTN 1101 Ancillary Cost-Effectiveness Analysis
BMT CTN 1101 辅助成本效益分析
  • 批准号:
    8702228
  • 财政年份:
    2012
  • 资助金额:
    $ 26.4万
  • 项目类别:
A Study of Cancer Diagnosis as a Risk Factor for Personal Bankruptcy
癌症诊断作为个人破产风险因素的研究
  • 批准号:
    7811272
  • 财政年份:
    2009
  • 资助金额:
    $ 26.4万
  • 项目类别:
Center for Comparative Effectiveness Research in Cancer Genomics - CANCERGEN
癌症基因组学比较有效性研究中心 - CANCERGEN
  • 批准号:
    7944022
  • 财政年份:
    2009
  • 资助金额:
    $ 26.4万
  • 项目类别:
Center for Comparative Effectiveness Research in Cancer Genomics - CANCERGEN
癌症基因组学比较有效性研究中心 - CANCERGEN
  • 批准号:
    7861060
  • 财政年份:
    2009
  • 资助金额:
    $ 26.4万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 26.4万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 26.4万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.4万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.4万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 26.4万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.4万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 26.4万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 26.4万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 26.4万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.4万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了